Johnson & Johnson's $14.6bn acquisition of Intra-Cellular Therapies adds Caplyta and a robust pipeline targeting major ...
Spotlighting innovation at the SCOPE Summit, finalists for the Site Innovation and Patient Engagement Awards showcase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback